In a divided opinion issued late Wednesday, the U.S. Court of Appeals for the Fifth Circuit ruled that the abortion medication mifepristone will remain approved for use throughout the United States, but only up to seven weeks of pregnancy when a doctor dispenses the medication in person. This ruling, if allowed to stand and followed, would significantly impair access to abortion throughout the United States.

“The Fifth Circuit’s decision to roll back recent measures that have ensured greater access to medication abortion care undermines the FDA’s authority and science, all while real people pay the price,” said Morgan Hopkins, president of All* Above All.